Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Iberoam Micol. 2009 Mar 31;26(1):56-61. doi: 10.1016/S1130-1406(09)70009-9. Epub 2009 May 7.

[Micafungin for the treatment of neonatal invasive candidiasis].

[Article in Spanish]

Author information

1
Servicio de Neonatología, Hospital Universitario 12 de Octubre, Madrid, España. eleninf@hotmail.com

Abstract

BACKGROUND:

In neonatal intensive care units, deep fungal disease due to Candida spp. are an important clinical problem, partly due to the increasing prevalence of Candida disease and also to the high associated and constant morbimortality; both factors are independently maintained though there has been a significant improvement in the management of neonatal patients.

AIMS:

To define the therapeutic use of micafungin for the treatment of neonatal invasive candidiasis.

METHODS:

We use a review of biomedic data bases namely Medline and EMBASE.

CONCLUSIONS:

Micafungin is the latest introduced echinocandin. It has a wide spectrum of activity and covers Candida albicans and non-albicans Candida species. It has scarce drugs interactions and is devoid of toxicity, being an attractive approach for the treatment of invasive candidiasis (without meningitis, endocarditis and endophthalmitis). Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates.

PMID:
19463278
DOI:
10.1016/S1130-1406(09)70009-9
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Revista Iberoamericana de Micologia-Asociacion Espanola de Micologia
    Loading ...
    Support Center